Evidence map›Paper›PMID 27449543›Full record

ReviewSmall GTPases2017

The mystery of oncogenic KRAS: Lessons from studying its wild-type counter part.

Yuan-I Chang, Alisa Damnernsawad, Guangyao Kong, Xiaona You, Demin Wang, Jing Zhang

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Small GTPases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Yuan-I Changa McArdle Laboratory for Cancer Research, University of Wisconsin-Madison , Madison , WI , USA.
Alisa Damnernsawada McArdle Laboratory for Cancer Research, University of Wisconsin-Madison , Madison , WI , USA.
Guangyao Konga McArdle Laboratory for Cancer Research, University of Wisconsin-Madison , Madison , WI , USA.
Xiaona Youa McArdle Laboratory for Cancer Research, University of Wisconsin-Madison , Madison , WI , USA.
Demin Wangd Blood Research Institute, Blood Center of Wisconsin , Milwaukee , WI , USA.
Jing Zhanga McArdle Laboratory for Cancer Research, University of Wisconsin-Madison , Madison , WI , USA.
University of Wisconsin–Madison · USVersiti Blood Center of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using conditional knock-in mouse models, we and others have shown that despite the very high sequence identity between Nras and Kras proteins, oncogenic Kras displays a much stronger leukemogenic activity than oncogenic Nras in vivo. In this manuscript, we will summarize our recent work of characterizing wild-type Kras function in adult hematopoiesis and in oncogenic Kras-induced leukemogenesis. We attribute the strong leukemogenic activity of oncogenic Kras to 2 unique aspects of Kras signaling. First, Kras is required in mediating cell type- and cytokine-specific ERK1/2 signaling. Second, oncogenic Kras, but not oncogenic Nras, induces hyperactivation of wild-type Ras, which significantly enhances Ras signaling in vivo. We will also discuss a possible mechanism that mediates oncogenic Kras-evoked hyperactivation of wild-type Ras and a potential approach to down-regulate oncogenic Kras signaling.

Indexed as

AnimalsGenes, rasHumansMutationleukemogenesisoncogenic Krasoncogenic NrasSOS1wild-type Kras

Identifiers

PMID27449543
PMCPMC5680677
OpenAlexW2485951722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.